Form 4: Outset Medical Executive Marc Nash Reports Stock Transactions Following Vesting of Performance-Based Units

Outset Medical's SVP of Operations and R&D, Marc Nash, reports the acquisition and sale of company stock following the vesting of performance-based restricted stock units.

Summary

• Marc Nash, SVP of Operations and R&D at Outset Medical, acquired 4,494 shares and 1,404 shares of common stock on January 17, 2025, due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on March 15, 2023, and July 24, 2023, respectively, and vested based on performance criteria as of December 31, 2024.
• The vesting was certified by the Compensation Committee of the Issuer's Board of Directors.
• Mr. Nash also sold 356, 21,590, 971, and 304 shares on January 21, 2025, at a price of $0.8 per share to cover tax withholding obligations related to the vesting of PSUs and performance-based restricted stock units (PRSUs).
• These sales were not discretionary trades but were required to satisfy tax obligations.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative news. The vesting of PSUs suggests that performance goals were met, which is a positive sign, but the subsequent sale of shares is a neutral event.

Positives

• The vesting of performance-based restricted stock units indicates that performance goals were met, which is a positive sign for the company.
• The executive's continued service through the vesting period is a positive indicator of commitment.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it is a standard practice.

Risks

• The document does not indicate any specific risks, but the sale of shares by an executive could potentially create short-term selling pressure on the stock.

Future Outlook

The remaining 50% of the PSUs granted on March 15, 2023, and July 24, 2023, will vest on December 31, 2025, subject to the reporting person's continuous service.

Industry Context

This type of stock transaction is common for executives who receive equity-based compensation. It reflects the standard practice of vesting schedules and tax obligations.

Comparison to Industry Standards

• The vesting of performance-based equity awards is a common practice across the technology and healthcare industries, aligning executive compensation with company performance.
• Companies like Medtronic and Baxter also use similar equity compensation structures for their executives.
• The 'sell to cover' transaction for tax obligations is a standard procedure in these industries.

Stakeholder Impact

• The vesting of PSUs and subsequent sale of shares may have a minor impact on shareholders due to the increase in shares and subsequent selling pressure, but this is a standard practice.
• The vesting of PSUs is a positive sign for employees as it indicates that performance goals were met.

Next Steps

• The remaining 50% of the PSUs will vest on December 31, 2025, subject to continued service.

Key Dates

Keywords

stock, performance-based restricted stock units, PSUs, vesting, tax withholding, insider trading, executive compensation, Outset Medical, OM, Marc Nash